Ultragenyx Pharmaceutical (RARE) said Friday it has resubmitted its biologics license application for accelerated approval of gene therapy UX111 to treat Sanfilippo syndrome type A to the US Food and Drug Administration.
The resubmission follows a complete response letter issued by the FDA in July and includes longer-term data on treatment benefits to back up a clinical endpoint for accelerated approval, the company said.
The updated data shows "a durable treatment effect" across multiple biomarkers and an "acceptable" safety profile, Ultragenyx said.
The company said it anticipates up to a six-month review period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments